Oncimmune Welcomes Study On Effectiveness Of EarlyCDT Platform

LONDON (Alliance News) - Oncimmune Holdings PLC, which is developing early cancer detection ...

Alliance News 20 September, 2016 | 11:04AM
Email Form

LONDON (Alliance News) - Oncimmune Holdings PLC, which is developing early cancer detection technology, on Tuesday welcomed a report in the Journal of Thoracic Oncology on the effectiveness of the firm's EarlyCDT platform.

The report demonstrated the effectiveness of using EarlyCDT-Lung tests to distinguish between malignant and benign lung nodules.

The study showed a positive earlyCDT-Lung test indicates a nodule is 2-3-times more likely to be a cancer, an important development for nodules which are too small for other methods of investigation to be effective.

"The ability to distinguish between malignant and benign lung nodules is a key challenge for physicians," said Geoffrey Hamilton-Fairey, Oncimmune's chief executive.

He added the study "adds further evidence that EarlyCDT-Lung can play a positive role in helping clinicians interpret pulmonary nodules and, significantly, do so when nodules are still small, leading to earlier detection."

Shares in Oncimmune were untraded on Tuesday, having last traded at 116.00 pence.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar Rating
Oncimmune Holdings PLC 111.00 GBX 0.00 -
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.